MUTE RECEIVES MAJOR REGULATORY APPROVALS 3 December 2014 Melbourne technology firm, Rhinomed (ASX:RNO) is pleased to announce that it has successfully completed the testing and technical documentation that has enabled its new novel snoring and sleep quality product – Mute™ to gain acceptance with the US Food and Drug Administration(FDA), European authority (CE Mark) and … Read more
RHINOMED RELEASES MUTE SLEEP TECHNOLOGY 8 December 2014 Melbourne bio-technology firm, Rhinomed (ASX:RNO) is pleased to announce the release of its newest device from it nasal respiratory technology stable of products, Mute™, a nasal breathing aid to alleviate snoring and improve sleep quality. Mute™ was successfully registered last week with the US FDA, Australian TGA and given permission to use the CE Mark … Read more
Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today released the Appendix 4E Preliminary Final Report Read a full copy of the report here.
Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today announced a pivotal year of growth and milestone achievement. The company can report record recognised revenues for FY18 Q4 of $874k – a 71% increase over FY18 Q3 and totalling $2.13m for the full FY18, up 24% on FY17. This came off the back of another … Read more
RHINOMED & US BASED COLUMBIA CARE TO DEVELOP NASALLY DELIVERED DOSE CONTROLLED CANNABIS BASED MEDICINES June 21, 2018, Melbourne, Australia. Melbourne based nasal respiratory company Rhinomed (ASX:RNO) is pleased to advise investors that it has signed a non-binding term sheet with Columbia Care LLC (“Columbia Care”) to license Rhinomed’s nasal platform for the delivery of medical … Read more
MUTE EXPANDS RANGING IN LEADING US PHARMACY – OVER 1100 NEW STORES ADDED June 19, 2018, Melbourne, Australia. Australian nasal and respiratory technology company Rhinomed (ASX:RNO) is pleased to advise investors that it has expended its relationship with one of America’s largest pharmacy retailer – CVS. The Company has now received initial purchase orders confirming that Mute … Read more
HALF YEARLY REPORT AND ACCOUNTS February 28, 2018. Melbourne, Australia. Rhinomed (ASX:RNO or “the Company) releases its half yearly report and accounts. Read a full copy of the report here.
RHINOMED’S MUTE AND TURBINE TECHNOLOGY RECEIVE REGULATORY CLEARANCE FOR CANADIAN DISTRIBUTION 3rd December, 2015. Melbourne, Australia. Australian medical technology company Rhinomed Ltd (ASX:RNO) today announced it has received its Medical Device Establishment Licence (MDEL) from Health Canada for the distribution of Turbine sports breathing technology and Mute snoring and sleep technology as Class … Read more
RHINOMED ANNOUNCES APPOINTMENT OF NEW DIRECTOR AND CHAIRMAN 1 st December, 2015. Melbourne, Australia. Rhinomed Ltd (ASX:RNO), today announced the appointment of a new director and Chairman Mr Ron Dewhurst. Mr Dewhurst will join the board as Chairman of the company following Mr Martin Rogers decision to step down as Chairman and as … Read more
RHINOMED’S MUTE™ SUCCESSFUL IN DEMONSTRATING EFFICACY AND BENEFIT IN SNORING TRIAL 2 December 2014 Melbourne technology firm, Rhinomed (ASX:RNO) today announced the topline results from its independent trial in snoring, sleep quality and night time nasal congestion which successfully demonstrated significant benefit of its new Mute nasal technology. The Company has submitted applications to the … Read more
